- Home
- ARQ vs LRMR Comparison
ARQ vs LRMR Comparison
Compare ARQ & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQ
- LRMR
- Stock Information
- Founded
- ARQ 1996
- LRMR N/A
- Country
- ARQ United States
- LRMR United States
- Employees
- ARQ N/A
- LRMR N/A
- Industry
- ARQ
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ARQ
- LRMR Health Care
- Exchange
- ARQ NYSE
- LRMR Nasdaq
- Market Cap
- ARQ 155.3M
- LRMR 183.8M
- IPO Year
- ARQ N/A
- LRMR N/A
- Fundamental
- Price
- ARQ $3.56
- LRMR $2.24
- Analyst Decision
- ARQ Strong Buy
- LRMR Strong Buy
- Analyst Count
- ARQ 1
- LRMR 9
- Target Price
- ARQ $8.00
- LRMR $19.00
- AVG Volume (30 Days)
- ARQ 232.2K
- LRMR 1.4M
- Earning Date
- ARQ 05-07-2025
- LRMR 04-30-2025
- Dividend Yield
- ARQ N/A
- LRMR N/A
- EPS Growth
- ARQ N/A
- LRMR N/A
- EPS
- ARQ N/A
- LRMR N/A
- Revenue
- ARQ $114,466,000.00
- LRMR N/A
- Revenue This Year
- ARQ $19.26
- LRMR N/A
- Revenue Next Year
- ARQ $24.97
- LRMR N/A
- P/E Ratio
- ARQ N/A
- LRMR N/A
- Revenue Growth
- ARQ 14.33
- LRMR N/A
- 52 Week Low
- ARQ $3.34
- LRMR $1.61
- 52 Week High
- ARQ $8.26
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- ARQ 40.35
- LRMR 47.46
- Support Level
- ARQ $3.58
- LRMR $2.03
- Resistance Level
- ARQ $4.40
- LRMR $3.07
- Average True Range (ATR)
- ARQ 0.26
- LRMR 0.30
- MACD
- ARQ 0.05
- LRMR 0.01
- Stochastic Oscillator
- ARQ 20.75
- LRMR 31.12
About ARQ ARQ INC
Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granula Activated Carbon, and Colloidal Carbon Product among others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.